Lupin gets US FDA approval for Sodium Zirconium Cyclosilicate oral suspension

Regulatory Product ApprovalBusiness Updates View source PDF Explain this filing

LUPIN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.9%Reaction day

₹2300.00

prior close

₹2285.00

announcement price

After-mkt

timing

Nifty Midcap 150market-0.0%-0.9% vs market

Pharmaceuticals peers, median of 164sector+0.1%-1.0% vs sector

On the reaction day the stock moved 0.9 pts less than Nifty Midcap 150 and 1.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.5

10m

-0.4

15m

-0.7

30m

-0.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.9-0.0-0.9+0.1-1.0

Next day

-1.6+0.2-1.8-0.4-1.2

-2.2+0.3-2.5+0.1-2.3

-2.8-0.2-2.6-0.4-2.4

-1.8-0.1-1.7-0.9-0.9

-3.0-0.5-2.5-0.5-2.5

-4.3-0.3-3.9-1.0-3.3

15d

-6.8-0.9-5.9-0.6-6.3

-8.9-2.7-6.3+1.1-10.1

-15.9-7.9-8.0-3.1-12.8

—————

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Lupin received US FDA approval for its generic Sodium Zirconium Cyclosilicate for Oral Suspension in 5g and 10g packets, rated bioequivalent to AstraZeneca's Lokelma used for treating hyperkalemia in adults. The reference drug had estimated annual US sales of around USD 568 million (IQVIA MAT Jun 2026), opening a sizeable market opportunity for Lupin's US generics business.

Likely market impact

Opens Lupin to a USD 568M US market segment for hyperkalemia treatment, supporting US revenue growth.